This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Informed consent.
Female patients aged ≥18 years and ≤ 75 years at time of inform consent signature
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Expected survival ≥ 3 months
Cervical cancer of other histology (e.g., neuroendocrine carcinoma, sarcoma)
Evidence of distant metastasis
Prior total hysterectomy (subtotal or cervical-sparing surgery allowed)
Unable or unwilling to receive brachytherapy